Lexpos News

/Lexpos News/

Evaluation of the QPS and PQS – one month left to share your views

Contractors (including head office staff) and community pharmacists have one month left to participate in an interview to share their views on the Quality Payments Scheme (QPS) (the previous name for the Pharmacy Quality Scheme (PQS)) and the PQS. ICF (an independent research consultancy) and the University of Manchester are carrying out the evaluation. The [...]

The post Evaluation of the QPS and PQS – one month left to share your views appeared first on PSNC Website.

By |May 24th, 2023|Lexpos News|Comments Off on Evaluation of the QPS and PQS – one month left to share your views

May 2023 Price Concessions 2nd Update

The Department of Health and Social Care (DHSC) has today (24/05/2023) granted the following list of price concessions for May 2023: Drug Pack size Price concession Amoxicillin 125mg/5ml oral suspension sugar free 100 £3.42 Amoxicillin 250mg/5ml oral suspension sugar free 100 £3.50 Atorvastatin 20mg tablets 28 £1.56 Bimatoprost 100micrograms/ml eye drops 3 £3.99 Clarithromycin 250mg/5ml oral [...]

The post May 2023 Price Concessions 2nd Update appeared first on PSNC Website.

By |May 24th, 2023|Lexpos News|Comments Off on May 2023 Price Concessions 2nd Update

Class 4 Medicines Defect Information: Metronidazole 200 mg/5 ml Oral Suspension (Drugsrus Limited / Dawa Limited)

Class 4 Medicines Defect Information: Metronidazole 200 mg/5 ml Oral Suspension (Drugsrus Limited / Dawa Limited) Drug alert number: EL (23)A/19 Date issued: 23 May 2023 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Product name:Metronidazole 200 mg/5 ml Oral Suspension, PL 30684/0236 Batch No [...]

The post Class 4 Medicines Defect Information: Metronidazole 200 mg/5 ml Oral Suspension (Drugsrus Limited / Dawa Limited) appeared first on PSNC Website.

By |May 23rd, 2023|Lexpos News|Comments Off on Class 4 Medicines Defect Information: Metronidazole 200 mg/5 ml Oral Suspension (Drugsrus Limited / Dawa Limited)

MHRA Class 4 Medicines Defect Information: Buccolam 10mg Oromucosal solution (Orifarm UK Ltd)

Class 4 Medicines Defect Information: Buccolam 10mg Oromucosal solution (Orifarm UK Ltd) Drug alert number: EL (23)A/18 Date issued: 22 May 2023 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Product name: Buccolam 10mg Oromucosal solution (Orifarm UK Ltd) PLGB 45985/0272 Batch No Expiry Date [...]

The post MHRA Class 4 Medicines Defect Information: Buccolam 10mg Oromucosal solution (Orifarm UK Ltd) appeared first on PSNC Website.

By |May 22nd, 2023|Lexpos News|Comments Off on MHRA Class 4 Medicines Defect Information: Buccolam 10mg Oromucosal solution (Orifarm UK Ltd)

No mandatory clinical audits in 2023/34

Community pharmacy contractors are not required to undertake a contractor-chosen or an NHS England determined clinical audit in 2023/24. This follows PSNC’s request to remove this clinical governance requirement for contractors in 2023/24. A clinical audit on anticoagulants is included in the Pharmacy Quality Scheme (PQS) 2023/24. If contractors choose to not participate in PQS, [...]

The post No mandatory clinical audits in 2023/34 appeared first on PSNC Website.

By |May 22nd, 2023|Lexpos News|Comments Off on No mandatory clinical audits in 2023/34